Skip to main content

A man who had lost 100 pounds over six months stopped his weight-loss drug in September 2025. One month later, he was admitted to a psychiatric hospital in a manic episode. He was speaking rapidly, acting on impulse, and gripped by an inflated sense of his own power. His lab tests came back almost entirely normal. His doctors had no clean explanation.

That case appears in a pair of case reports. So does an equally unsettling one involving a 61-year-old who developed hallucinations and a belief that he was dead. The reports have added an unexpected question to the conversation about GLP-1 receptor agonists. That is the class of drugs that includes Ozempic, Wegovy, Mounjaro, and Zepbound. These are among the most widely used drugs on the planet. The reports do not prove that stopping them causes psychiatric illness. They do raise a concern that going off the drugs may involve more than weight coming back.

The two cases did not involve Ozempic specifically. Both patients had been taking tirzepatide, sold under the brand names Mounjaro and Zepbound. Ozempic (semaglutide) belongs to the same drug class and works in related ways. These reports should not be read as evidence that Ozempic causes psychosis.

Editor’s note: The headline names Ozempic and talks about users experiencing psychotic side effects after quitting. The two published case reports involve tirzepatide (Mounjaro and Zepbound), not Ozempic. They are two cases, not proof that stopping the drug caused the symptoms. Both men had prior mental health histories.

How many people actually stop these drugs?

The rate at which people stop GLP-1 drugs is high. More than 4,400 lawsuits involving GLP-1 drugs are pending in federal court against Novo Nordisk and Eli Lilly. Legal pressure is one sign of a broader problem with how well people can stay on the drugs. Roughly one in three people prescribed a GLP-1 drug never makes it past six months. Cost, side effects, supply problems, and limited insurance coverage all play a role. They push a large share of users off these drugs far sooner than their doctors intended. A 2026 analysis published in The Lancet found that between 20% and 50% of patients interrupt these drugs. That happens within the first year of starting them.

The physical effects of stopping are already well documented. A 2025 study found that 60% of the weight lost during treatment is regained within one year of stopping. Blood sugar and metabolic markers also worsen quickly. Trial data show that HbA1c and glucose levels rise after GLP-1 withdrawal. People with type 2 diabetes need close medical monitoring in that period.

Read More: What Really Happens to Your Body When You Quit Ozempic

What did the two case reports describe?

The case reports published in the Primary Care Companion for CNS Disorders describe two men. Both had pre-existing mental health histories. Both developed serious psychiatric symptoms after stopping tirzepatide. These are only two cases. They don’t prove the drug caused what happened. But their severity is hard to dismiss.

The first patient was a 61-year-old man with a history of depression. He stopped tirzepatide in August 2025 because of nausea. Two months later, he was hospitalized for worsening confusion and erratic behavior. Doctors found he was experiencing paranoia, auditory and visual hallucinations, and Cotard’s delusion. That is a rare condition in which a person holds the belief that they are dead or don’t exist. His brain MRI, spinal fluid tests, and EEG all came back normal. An EEG is a test that measures electrical activity in the brain. That helped rule out several other potential causes. Antipsychotics first stabilized him enough to go home. He was later readmitted for a catatonic episode, becoming motionless and unresponsive. He later needed hospital care and electroconvulsive therapy (ECT). ECT uses brief electrical pulses to stimulate the brain. It is typically reserved for the most severe and hard-to-treat psychiatric episodes.

The second case involved a 52-year-old man with a history of anxiety. He stopped the same drug abruptly in September 2025 after losing 100 pounds over six months. One month later, he was admitted to a mental health facility. He met the criteria for a manic episode. His symptoms included rapid and unclear speech, acting on impulse, and irritability. He also showed grandiosity, an unrealistic sense of uniqueness or power. He needed psychiatric care and treatment with antipsychotics. Again, his tests came back essentially normal, with the minor exception of a low vitamin B12 level.

It remains unclear whether the psychiatric symptoms were directly linked to the discontinuation of tirzepatide. Both men had pre-existing mental health conditions, and that history matters. The authors are careful to say so. The authors of the case reports called for more research into the mental health effects of stopping these drugs. They also said the issue may often go unrecognized in the clinic.

Why would the brain be involved at all?

GLP-1 receptors aren’t confined to the gut and pancreas. Research published in 2025 found that turning on GLP-1 receptors in key brain regions can change several chemical messenger systems. Those include dopamine and serotonin, as well as glutamatergic and GABAergic transmission. These systems influence behavior, mood, and thinking. They also help regulate motivation and the sense of reward.

Dopamine is a key part of this picture. A 2025 study looked at the ventral tegmental area, or VTA. This brain region acts as a central hub for dopamine. It found that GLP-1 suppresses GABAergic inhibition. That can ease the way for dopamine signaling and reduce food-motivated behaviors. When a drug that has been changing this circuit for months is suddenly withdrawn, the system doesn’t simply spring back. It does not return to its baseline right away. That disruption, according to the case report authors, may add to psychotic or manic symptoms in people who are already vulnerable.

GLP-1 drugs may cross the blood-brain barrier and directly affect the brain and spinal cord, according to a 2025 review. The blood-brain barrier is the tight filter that controls what enters the brain.

The case report authors also raise the possibility that GLP-1 drugs may reduce inflammation in the brain and spinal cord while they’re being taken. Withdrawal could allow that inflammation to return or rebound, they suggest. That might add to mental instability. This remains a hypothesis, not a proven cause.

What does the broader evidence show?

The GLP-1 psychotic symptoms documented in these two cases exist against a background that is otherwise mostly reassuring.

In January 2026, the FDA asked makers of GLP-1 weight-loss drugs to remove warnings about suicidal thoughts from their labels. The request covered drugs including Wegovy and Zepbound. This decision followed a review of 91 placebo-controlled trials and a large claims-based group study. That review found no increased risk of suicidal thoughts, attempts, or other mental health events with these drugs. That’s a substantial body of evidence.

A large Swedish national group study followed roughly 95,500 people with depression or anxiety and was published in 2026. It found that semaglutide users were 42% less likely to have worsening mental health symptoms, including hospital stays and self-harm. That was compared with periods when the same people were not on the drug. A 2026 review of 86 randomized trials found no major difference in anxiety between GLP-1 drugs and control treatments. In clinical trials of tirzepatide, the psychiatric stop rate was 0.3% across all doses. That is the rate at which patients stopped the drug because of mood or anxiety symptoms.

A 2026 report in Frontiers in Drug Safety and Regulation also described panic attacks around the time two women stopped tirzepatide. Both women had recurrent depressive disorder. The report adds another reason to look closely at the move off the drug, especially a sudden one. It does not, on its own, prove that stopping the drug caused the panic attacks.

If you’ve been following the broader physical effects of stopping these drugs, a similar pattern holds. The body, and possibly the brain, may react to an abrupt withdrawal in ways that are not yet fully understood.

What should you do if you want to stop a GLP-1 drug?

Do not stop a GLP-1 drug abruptly on your own. Both patients in these reports quit without a medically supervised taper. Whether or not the drug directly caused their symptoms, an abrupt withdrawal removed a possible stabilizing effect. That is the effect the medication may have been having on their brain chemistry. The results were severe enough to require hospitalization in both cases.

If you’re thinking about stopping or changing your GLP-1 drug for any reason, talk with your prescribing doctor first. That includes cost, side effects, weight goals reached, or simply wanting a break. This is especially true if you have any personal history of depression, anxiety, bipolar disorder, or any other mental health condition. The cases described in the Primary Care Companion for CNS Disorders both involved men with existing mental health histories. That vulnerability appears to be a relevant factor in who might be at risk.

Ask your doctor about a gradual taper rather than a cold stop. Ask how to monitor your mood during the transition, and what symptoms should prompt you to reach back out quickly. A drug that affects dopamine, serotonin, and the brain’s reward system should be stopped with careful medical supervision. The same care applies to any other drug that touches the central nervous system. This is not a reason to start, stop, or change any medication on your own.

Disclaimer: The author is not a licensed medical professional. The information provided is for general informational and educational purposes only and is based on research from publicly available, reputable sources. It is not intended to constitute, and should not be relied upon as, medical advice, diagnosis, or treatment. Always consult a licensed physician or other qualified healthcare provider regarding any medical condition, symptoms, or medications. Do not disregard, avoid, or delay seeking professional medical advice or treatment because of information contained herein.

AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.